Lars Bastholt
Overview
Explore the profile of Lars Bastholt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
10770
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pedersen S, Johansen E, Hojholt K, Pedersen M, Mogensen A, Petersen S, et al.
Eur J Cancer
. 2025 Jan;
217:115253.
PMID: 39874911
Introduction: Advances in modern therapies have improved outcomes for patients with melanoma brain metastases (MBM), though prognosis remains poor. The optimal treatment strategy for patients who do not meet clinical...
2.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.
Eur J Cancer
. 2024 Dec;
215:115153.
PMID: 39709737
A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was...
3.
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.
Eur J Cancer
. 2024 Dec;
215:115152.
PMID: 39700658
This guideline was developed in close collaboration with multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF) and the European Organization for Research and Treatment...
4.
Jurlander R, Guldbrandt L, Holmstroem R, Madsen K, Donia M, Haslund C, et al.
Eur J Cancer
. 2024 Oct;
212:115053.
PMID: 39405648
Introduction: Immune checkpoint inhibitors (ICIs) carry the risk of immune-related adverse events (irAEs), a significant concern as therapy has transitioned to the adjuvant setting. Balancing therapeutic benefits against potential risks...
5.
Leboulleux S, Kapiteijn E, Litiere S, Schoffski P, Godbert Y, Rodien P, et al.
Front Endocrinol (Lausanne)
. 2024 Jul;
15:1403687.
PMID: 39015176
Background: Nintedanib is a triple-angiokinase inhibitor with potential activity in patients with advanced thyroid cancers, as radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC). Design: EORTC-1209...
6.
Brose M, Capdevila J, Elisei R, Bastholt L, Fuhrer-Sakel D, Leboulleux S, et al.
Endocr Relat Cancer
. 2024 Jun;
31(8).
PMID: 38828895
The VERIFY study aimed to determine the efficacy of vandetanib in patients with differentiated thyroid cancer (DTC) that is either locally advanced or metastatic and refractory to radioiodine (RAI) therapy....
7.
Petersen S, Hansen C, Ellebaek E, Schmidt H, Aaquist Haslund C, Ruhlmann C, et al.
Eur J Cancer
. 2024 May;
205:114099.
PMID: 38754294
Aim: The objective of this study was to evaluate whether patient biological sex influences treatment outcomes in patients with metastatic melanoma (MM) undergoing first-line immune checkpoint inhibitor (ICI) therapy. Methods:...
8.
Christensen S, Winther M, Laursen I, Madsen F, Brink C, Brix T, et al.
Support Care Cancer
. 2024 Apr;
32(5):281.
PMID: 38598052
Purpose: Immune-related thyroid adverse events (irTAEs) occur frequently following immune checkpoint inhibitor (ICI) therapy. The purpose of this study is to provide knowledge about the incidence, clinical timeline characteristics, associated...
9.
Holmstroem R, Pedersen S, Jurlander R, Madsen K, Donia M, Ruhlmann C, et al.
Eur J Cancer
. 2024 Mar;
202:114023.
PMID: 38518533
Background: Clinical trials have demonstrated promising outcomes for adjuvant immunotherapy in patients with resected melanoma. Real-life data provide valuable insights to support patient guidance and treatment decisions. Methods: Observational population-based...
10.
Ellebaek E, Khan S, Bastholt L, Schmidt H, Aaquist Haslund C, Donia M, et al.
Eur J Cancer
. 2024 Jan;
198:113476.
PMID: 38171116
Background: Metastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless of tumor PD-L1 expression. Methods: We conducted a population-based study including all patients with MM...